title: Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.
abstract: Autoantibodies against p53 have been observed in many cancers, often linked with abnormalities in the TP53 gene. Since p53 mutations and deletions at chromosome 17p are known to occur in CLL, we measured anti-p53 autoantibodies by ELISA in plasma samples from patients with normal cytogenetics as well as those with 13q, 11q, and 17p deletions as well as trisomy 12. Anti-p53 autoantibodies were detected in over half of the patients with a 17p deletion but in very few of the others. There was no correlation between the levels of anti-p53 antibodies and the percentage of cells with 17p abnormalities. The levels of the anti-p53 autoantibodies remained stable for most patients with serial samples. Increased levels of antibodies that bound to two peptide fragments of p53 were also seen in patients with 17p deletions. At least on case with high levels of anti-p53 autoantibodies had a heterozygotic mutation known to result in a dominant negative phenotype, suggesting that aberrant expression of p53 may contribute to the development of autoantibodies and suggests that these autoantibodies may reflect biological features relevant to prognosis.
authors.affiliation: Moores Cancer Center, Department of Medicine, 3855 Health Sciences Dr, University of California San Diego, La Jolla, CA 92093-0815, USA. bmessmer@ucsd.edu
authors.forename: Bradley T
authors.initials: BT
authors.lastname: Messmer
authors.forename: Talia S
authors.initials: TS
authors.lastname: Nour-Omid
authors.forename: Emanuela
authors.initials: E
authors.lastname: Ghia
authors.forename: Ana B
authors.initials: AB
authors.lastname: Sanchez
authors.forename: Thomas J
authors.initials: TJ
authors.lastname: Kipps
mesh_terms: D001323:Autoantibodies / Q000276:immunology*; D015153:Blotting, Western; D016022:Case-Control Studies; D002872:Chromosome Deletion; D002886:Chromosomes, Human, Pair 17 / Q000235:genetics*; D004797:Enzyme-Linked Immunosorbent Assay; D006579:Heterozygote; D006801:Humans; D017404:In Situ Hybridization, Fluorescence; D007621:Karyotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000235:genetics* / Q000276:immunology*; D009154:Mutation / Q000235:genetics; D010446:Peptide Fragments / Q000276:immunology / Q000378:metabolism; D011379:Prognosis; D015996:Survival Rate; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000276:immunology*
chemical_list: D001323:Autoantibodies; D010446:Peptide Fragments; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53